Human papilloma virus infection in non-cancerous versus normal esophageal tissue samples by endoscopy

Abstract

Background: Cancers are the second most common cause of non-accidental deaths in Iran, after cardiovascular mortality. Although most cases of esophageal squamous cell carcinoma (ESCC) in the USA and western populations have been attributed to high levels of exposure to tobacco and alcohol, but in Iranian populations, other risk factors especially infectious agents have been postulated as possible causes, particularly human papillomavirus (HPV). This study aimed to determine the prevalence and the types of HPV infection in biopsy samples taken from non-cancerous esophageal lesions during upper endoscopy.

Methods: A total of 80 non-cancerous esophageal samples were collected in paraffinated blocks of tissue archives in pathology. After DNA extraction, qualitative PCR (qPCR) was performed using the HPV L1 primer pairs MY09/MY11 and then genotyping was performed in HPV DNA positive by Real time PCR.

Results: From 80 cases, 29 (36.3%) were qPCR positive. Using the Real-time PCR method, a total of 14 HPV genotypes were assessed. We detected HPV-11 as a dominant type in this study and we did not find any type of HPV-16 and 18 genotypes.

Conclusion: In this study, HPV-II was the most common type in esophageal samples, in contrast we have found no oncogenic HPV like HPV 16 and 18 which are the most known responsible factors of ESCC in other countries.

Keywords: HPV (Human Papilloma virus); esophagitis; normal tissue; non-cancer; Real-Time PCR.

Citation: Mostafalou N, Yahyapour Y, Sedaghat S, et al. Human papilloma virus infection in non-cancerous versus normal esophageal tissue samples by endoscopy. Caspian J Intern Med 2015; 6(1): 9-14.
Both histological subtypes of esophageal malignancies, including squamous cell carcinoma (SCC) and adenocarcinoma (ADC) are highly lethal with a current five-year survival of less than 10% (8). In the USA and other western countries, tobacco, too much drinking alcohol, diets poor in fresh fruits and vegetables, and low socioeconomic group have been associated with esophageal SCC (7, 9). In Iran and China, alcohol and tobacco are not considered as risk factors for esophageal cancer (7, 10-14).

Human papilloma virus (HPV) is a viral agent associated with esophageal cancer thus far. HPV, especially genotypes of 16 and 18, were the major cause in uterine cervical carcinoma and has a strong association with cancers of the vulva, anus, penis, oropharynx and esophagus (15). HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82 are classified as high-risk (HR) oncogenic types; types 6, 11, 40, 42, 44, 54, 61, 70, 72, 81, and CP6108 are classified as low-risk (LR) types; and types 26, 53, and 66 are considered as probably oncogenic. Also, HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 66 are carcinogenic to humans (Group 1). HPV 6 and HPV 11 (Group 2B) and some types of HPV genus beta are possibly carcinogenic to human (Group 2B) (16). Serologic studies as well as studies considering HPV-DNA (17) revealed inconsistent data and found the evidence of exposure to HPV in 0-67% of cases (18, 19).

In many Iranian studies, esophageal SCC was associated with HPV 16 but not HPV 18 (20). Most infected people are asymptomatic and so HPV infection will be unrecognized because the immune system inactivates the virus. In about 90% of people, the immune system clears the HPV infection within 2 years.

This is true for both the high-risk and low-risk HPV types. Sometimes HPV infections are not clear and results in cell changes which may predispose the infected to the development of future cancers (21). The present study aimed to assess HPV infection in samples provided during endoscopy from patients with non-cancerous lesions or normal esophagus.

Methods
Subjects: A total of 80 non-cancerous esophageal samples were collected. The presenting symptoms in 48 patients was dyspepsia, 20 patients had heart burn, and 12 patients with dysphagia. 57 samples were provided from Shahid Beheshti Hospital, one of the big hospitals in Babol, a city in Mazandaran, North of Iran; 23 samples were obtained from Central Lab of Amol, a city, west of Babol. Demographic and medical information including age, gender, resident, smoking and type of lesion were obtained from the patients’ medical records. Based on pathology diagnosis, the parafinmat blocks of tissue-archive in two centers in patients with non-cancerous esophageal lesion were entered in our study.

DNA extraction and Real Time PCR: The methods were described previously (16, 22). After DNA extraction, Real-time PCR was performed with the Corbett Rotor-Gene 6000 Sequence Detection System and SYBR-Green PCR master mix (Maxima® SYBR Green qPCR Master Mix (2X), Applied Fermentas, EU). The primers used in this study were general primers from MY09 and MY011 pairs (MY09: 5'-CGT CCM AAR GGA WAC TGA TC; MY011: 5'-GCM CAG GGW CAT AAY AAT GG-3').

All HPV-DNA positive specimens of esophageal biopsy with non-cancerous lesion for HPV genotyping performed with high-sensitive real-time PCR (Rotor Gene 6000, Corbett Research, Australia & USA) by AmpliSense HPV HCR genotype FRT PCR Kit for High-Risk genotyping using AmpliSense HPV 6/11 FRT PCR Kit for the detection of Low-risk genotyping (Federal State Institution of Science Central Research Institute of Epidemiology, 3A Novogireevskaya Street Moscow 111123 Russia).

Results
The patients were 42 to 90 years old and their mean±SD age was 65±12.3 years. The characteristics of patients and the frequency of HPV infection were presented in table 1.

Using the Real-time PCR method, a total of 14 genotypes including HPV6, 11, 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58 and 59 were analyzed. As seen in table 2, we detected HPVs-11 (in 4 cases), 33 (in one case), 56 (in 2 cases) and HPV-56 (in one case) of patient with inflammation. Also, HPVs-11, 39 and 52 were detected in only one case of patient with dysplasia. The most prevalent genotype was HPV11 (17.2%; 5.29) of the HPV positive cases (36.25%; 29.80) and the second more prevalent genotype was HPV 56 with 6.9% (2.29). Also, HPV was found in 8 inflammatory samples in 4 cases, HPV 33 and 58 in one case and HPV 56 in 2 cases). In 12 dysplastic samples, 3 genotypes of HPV including HPV-11, 39 and 52 were detected.
Table 1: Patient characteristics and frequency of HPV according to subgroups.

|                          | N(%) | P-value | HPV+ N (%) |
|--------------------------|------|---------|------------|
| **Gender**               |      |         |            |
| Male                     | 48 (60) | 0.483  | 18 (37.5)  |
| Female                   | 32 (40) |         | 11 (34.3)  |
| **Age**                  |      |         |            |
| <50                      | 11 (13.7) |         | 3 (27.3)   |
| 50 to 65                 | 27 (33.7) | 0.521  | 11 (40.7)  |
| ≥ 65                     | 42 (52.5) |         | 15 (35.7)  |
| **Histopathological diagnosis** |      |         |            |
| Inflammation             | 51 (63.7) |         | 20 (39.2)  |
| Dysplasia                | 12 (15) | 0.955  | 4 (33.3)   |
| Barrett’s esophagus      | 4 (5)  |         | 1 (25)     |
| Normal tissue            | 13 (16.2) |         | 4 (30.8)   |
| **Resident**             |      |         |            |
| Urban                    | 44 (55) | 0.001  | 23 (52.3)  |
| Rural                    | 36 (45) |         | 6 (16.7)   |

**Discussion**

In our study, from the 80 cases with tissue diagnosis of non-malignant esophageal lesions, the prevalence of HPV-DNA in these samples with Real Time PCR was 36.3%. We reported, 20 (39.2%) HPV DNA in esophagitis samples and others were 29.6% (23), 58.8% (24) and 26% (25). Also, we reported 4 (33%) HPV DNA in dysplasia. This is less than in Mohiuddin’s 71.4% (24) and Liu’s studies about 70% (26). In our study, 1 (25%) HPV DNA in Barrets samples and other studies reported 96% (25), 27.4% (27), 1.7% (28), respectively. We reported 4 (30.8%) HPV DNA in normal samples and other researchers showed 45.7% (24), 33% (26) and 24.1% (27).

Many studies were performed in different geographic parts of Iran, from northeast of Iran (29), northwest of Iran (30), north of Iran (31) and central of Iran (20), HPV prevalence reported 49.4% (in ESCC), 37.7% (in ESCC), 12.5% (in non-cancerous samples) and 13.2% (in non-cancerous samples), respectively.

Other studies from many countries including China (0-71%) (17, 32, 33); India (57.8%) (24); Brazil (0.0%) (34); Italy (29.6% in esophagitis) (23) and Australia (0.0% in normal tissue samples) (35) have reported the patients with non-malignant esophageal. Therefore, in our study we found 36.3% HPV DNA in non-malignant esophageal patients that is similar to many areas of China and less than India, but greater than Brazil, Italy and Australia. Several studies reported different prevalence of HPV in normal and malignant tissue and the range of positivity was between 0–82% (17, 32).

Yahyapour et al. reported HPV in 27% of ESCC patients. They found one case of HPV-16 and one case of HPV-18. They reported the highest genotypes HPV 11 & 45. Also, they reported the etiology of HPV 16 & 18 for infection of by cancer in the North of Iran (16, 20). Therefore, many studies in the North of Iran are similar to our study and confirmed some high risk HPV genotypes (HPV-16 and 18) are not as a main risk factor for esophageal disease (16). However, Liu et al. reported HPV-16, 18, 58, 31 as high risk types and HPV-6 and 11 as low risk types in dysplasia and normal tissue samples (26). In Acevedo-Nuno’s study, the major HPV viral types detected by PCR in positive samples were strains 6 and 11, while less frequent were strains 18, 31, 33, 35, 51 and 58 (25). Many HPV genotypes including 11, 33, 39, 52, 56 and 58 were detected and HPV 11 was the dominant type in this study (17.2%; 5/29) of the HPV positive cases (36.25%; 29/80) and the second more prevalent genotype was HPV 56 with 6.9% (2/29) (table 2). In our study, we did not find HPV 16 &18 genotypes, similar to Yahyapour (16, 22), Farhadi (20) and Antonsson’s (35) studies and are different from Tahmasbi (36) and Emadian’s
Acknowledgments

We would like to thank Dr. Joghataei, Ms. Bakhshayesh, of Cellular and Molecular Research Center, Iran University of Medical Sciences, (for Real-Time PCR test) the Pathology Lab. Personnel of Shahid Beheshti Hospital and Amol Central Laboratory.

Funding: This study was supported by a grant (number 923547) from Babol University Infections Diseases and Tropical Medicine Research center. Also, this article is a thesis of an internal medicine resident.

Conflict interest: There was no Conflict of Interest.

References
1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
2. Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 2006; 24: 2137-50.
3. Ries LAG, Eisner MP, Kosary CL, et al. SEER cancer statistics review, 1975-2000. Bethesda, MD: National Cancer Institute 2003.
4. Ferlay J, Bray F, Pisani P, Parkin DM. Globocan 2000: Cancer incidence, mortality and prevalence worldwide. Lyon: IARC Press 2001.
5. Brown LM, Hoover R, Silverman D, et al. Excess incidence of squamous cell esophageal cancer among US Black men: role of social class and other risk factors. Am J Epidemiol 2001; 153: 114-22.
6. Zou XN, Taylor PR, Mark SD, et al. Seasonal variation of food consumption and selected nutrient intake in Linxian, a high risk area for esophageal cancer in China. Int J Vitam Nutr Res 2002; 72: 375-82.
7. Tran GD, Sun XD, Abnet CC, et al. Prospective study of risk factors for esophageal and gastric cancers in the Linxian general population trial cohort in China. Int J Cancer 2005, 113: 456-63.
8. Sadjadi A, Nouriaie M, Mohagheghi MA, et al. Cancer occurrence in Iran in 2002, an international perspective. Asian Pac J Cancer Prev 2005; 6: 359-63.
9. Samadi F, Babaei M, Yazdanbod A, et al. Survival rate of gastric and esophageal cancers in Ardabil province, North-West of Iran. Arch Iran Med 2007; 10: 32-7.
10. Nasrollahzadeh D, Kamangar F, Aghcheli K, et al. Opium, tobacco, and alcohol use in relation to
HPV infection in non-cancerous lesions of esophagus

oesophageal squamous cell carcinoma in a high-risk area of Iran. Br J Cancer 2008; 98: 1857-63.

11. Sepehr A, Kamangar F, Fahimi S, et al. Poor oral health as a risk factor for esophageal squamous dysplasia in Northeastern Iran. Anticancer Res 2005; 25: 543-6.

12. Isami F, Kamangar F, Aghchekili K, et al. Epidemiologic features of upper gastrointestinal tract cancers in Northeastern Iran. Br J Cancer 2004; 90: 1402-6.

13. Akbari MR, Malekzadeh R, Nasrollahzadeh D, et al. Familial risks of esophageal cancer among the Turkmen population of the Caspian Littoral of Iran. Int J Cancer 2006; 119: 1047-51.

14. Taghavi N, Nasrollahzadeh D, Merat S, et al. Epidemiology of upper gastrointestinal cancers in Iran: A sub site analysis of 761 cases. World J Gastroenterol 2007; 13: 5367-70.

15. Gillison ML, Shah KV. Chapter 9: Role of mucosal human papillomavirus in nongenital cancers. J Natl Cancer Inst Monogr 2003; 31: 57-65.

16. Yahyapour Y, Shamsi-Shahrabi M, Mahmoudi M, et al. High-risk and low-risk human papillomavirus in esophageal squamous cell carcinoma at Mazandaran, Northern Iran. Pathol Oncol Res 2013; 19: 385-91.

17. Zhang QY, Zhang DH, Shen ZY, et al. Infection and integration of human papillomavirus in esophageal carcinoma. Int J Hyg Environ Health 2011; 214: 156-61.

18. Syrjanen KJ. HPV infections and oesophageal cancer. J Clin Pathol 2002; 55: 721-8.

19. Kamangar F, Qiao YL, Schiller JT, et al. Human papillomavirus serology and the risk of esophageal and gastric cancers: Results from a cohort in a high-risk region in China. Int J Cancer 2006; 119: 579-84.

20. Farhadi M, Tahmasebi Z, Merat S, et al. Human papillomavirus in squamous cell carcinoma of esophagus in a high-risk population. World J Gastroenterol 2005; 11: 1200-3.

21. American Cancer Society. Human Papilloma Virus (HPV), Cancer, HPV Testing, and HPV Vaccines: Frequently Asked Questions. Available at: www.cancer.org/hpv-faq-pdf

22. Yahyapour Y, Shamsi-Shahrabi M, Mahmoudi M, et al. Evaluation of Human Papilloma Virus Infection in Patients with Esophageal Squamous Cell Carcinoma from Near the Caspian Sea, North of Iran. Asian Pac J Cancer Prev 2012; 13: 1261-6.

23. Tornesello ML, Monaco R, Nappi O, Buonaguro L, Buonaguro FM. Detection of mucosal and cutaneous human papillomaviruses in esophagitis, squamous cell carcinoma and adenocarcinoma of the oesophagus. J Clin Virol 2009; 45: 28-33.

24. Mohiuddin MK, Chava S, Upendrum P, et al. Role of human papilloma virus infection and altered methylation of specific genes in esophageal cancer. Asian Pac J Cancer Prev 2013; 14: 4187-93.

25. Acevedo-Nuno, Gonzalez-Ojeda A, Vazquez-Camacho G, et al. Human papillomavirus DNA and protein in tissue samples of oesophageal cancer, Barrett’s oesophagus and oesophageal cancer. Anticancer Res 2004; 24: 1319-24.

26. Liu HY, Zhou SL, Ku JW, et al. Prevalence of human papillomavirus infection in esophageal and cervical cancers in the high incidence area for the two diseases from 2007 to 2009 in Linzho of Henan Province, Northern China. Arch Virol 2014; 159: 1393-401.

27. Iyer A, Rajendran B, Adamsonb CS, et al. Human papillomavirus is detectable in Barrett’s esophagus and esophageal carcinoma but is unlikely to be of any etiologic significance. J Clin Virol 2011; 50: 205-8.

28. Rai N, Jenkins GI, McAdam E, et al. Human papillomavirus infection in Barrett’s oesophagus in the UK: An infrequent event. J Clin Virol 2008; 43: 250-2.

29. Moradi AV, de Villers EM, Mokhtari-Azad T, et al. Detection of human papillomavirus DNA by PCR in esophageal squamous cell carcinoma from Turkmen Sahra, North-East of Iran. Iranian Biomed J 2002; 6: 19-23.

30. Mohseni Mehran SM. Detection of human papilloma virus in esophageal squamous cell carcinoma in Guilan province. J Clin Diagn Res 2010; 4: 2373-7.

31. Emadian O, Naghshvar F, Rafiei AR, et al. Correlation of human papillomavirus infection with esophageal squamous cell carcinoma. J Babol Univ Med Sci 2011; 13: 54-9. [in Persian]

32. Zhang D, Zhang Q, Zhou L, et al. Comparison of prevalence, viral load, physical status and expression of human papillomavirus -16, -18 and -58 in esophageal and cervical cancer: a case-control study. BMC Cancer 2010; 10: 650.

33. Qi Z, Giang Q, Yang G, et al. Human papillomavirus (HPV) infection and the risk of esophageal squamous cell carcinoma. Dis Esophagus 2013; 26: 61-7.
34. Antunes LC, Prolla JC, de Barros Lopes A, da Rocha MP, Fagundes RB. No evidence of HPV DNA in esophageal squamous cell carcinoma in a population of Southern Brazil. World J Gastroenterol 2013; 19: 6598-603.

35. Antonsson A, Nancarrow DJ, Brown IS, et al. High-Risk human papillomavirus in esophageal squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2010; 19: 2080-7.

36. Dąbrowski A, Kwaśniewski W, Skoczylas T, Bednarek W, Kuźma D. Incidence of human papilloma virus in esophageal squamous cell carcinoma in patients from the Lublin region. World J Gastroenterol 2012; 18: 5739-44.

37. Tahmasebi Fard Z, Farhadi Langeroudi M, Malekzadeh R, et al. Human papillomavirus in squamous cell carcinoma of esophagus in a high-risk population. Govaresh 2004; 9: 6-22. [in Persian]

38. Cook-Mozaffari PJ, Azordean F, Day NE, et al. Oesophageal cancer studies in the Caspian littoral of Iran: results of a case-control study. Br J Cancer 1979; 39: 293-309.